Overview

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites

Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy of a 2-week course of tolvaptan in improving serum sodium and the excretion of extracellular fluid in liver cirrhotic patients with ascites and hyponatremia
Phase:
Phase 4
Details
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.
Treatments:
Tolvaptan